Compare Mechanisms: Which Weight Loss Injection Suits You?
Mounjaro vs Wegovy Weight Loss: Understanding Prescription Options
When comparing Mounjaro vs Wegovy weight loss treatments, the fundamental difference lies in their mechanisms of action. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural fullness hormone to reduce appetite and promote satiety after smaller meals. Mounjaro, containing tirzepatide, is a dual-acting medication that targets both GIP and GLP-1 receptors, potentially offering a different approach to weight management.
Both medications require a prescription-only medicine status and must be used alongside a reduced-calorie diet and increased physical activity. The choice between these Mounjaro vs Wegovy weight loss options often depends on individual patient factors, medical history, and prescriber recommendation. At EverydayMeds, we stock Wegovy as our primary weight loss injection, backed by extensive STEP trial data and NICE recommendation TA875.
Wegovy Pricing: Transparent Costs for Weight Loss Prescription
Understanding the investment in your Mounjaro vs Wegovy weight loss journey starts with clear pricing. Wegovy follows a structured dose escalation: 0.25mg starter pens cost £79.99, progressing to 0.5mg at £94.99, 1mg at £99.99, 1.7mg at £139.99, and maintenance 2.4mg at £209.99. New customers apply discount code FIRST40 at checkout to achieve these final prices, whilst returning customers use DOSE25.
Our convenient bundles provide continuous supply without multiple orders. The Intro Duo (0.25mg & 0.5mg) costs £169.99, covering your first 8 weeks, whilst the Progress Trio (0.5mg, 1mg & 1.7mg) at £369.99 provides 12 weeks of step-up dosing. For maintenance patients, the Ultimate Stability Trio offers three 2.4mg pens for £649.99, ensuring uninterrupted treatment when comparing ongoing Mounjaro vs Wegovy weight loss costs.
Clinical Evidence: STEP Trials Supporting Wegovy Weight Loss
The Mounjaro vs Wegovy weight loss debate benefits from examining robust clinical evidence. Wegovy's efficacy comes from the comprehensive STEP trial programme, with STEP 1 demonstrating approximately 15% average weight loss at 68 weeks versus 2.4% with placebo (Wilding et al., NEJM, 2021). STEP 2 showed clinically studied weight loss in patients with type 2 diabetes, whilst STEP 3 achieved 16% when combined with intensive behavioural therapy.
The recent SELECT trial revealed Wegovy's cardiovascular benefits, showing a 20% reduction in major cardiovascular events. When evaluating Mounjaro vs Wegovy weight loss options, it's important to note that different trial designs and patient populations make direct comparisons inappropriate, but both medications have demonstrated significant efficacy in their respective studies.
How Wegovy Works: GLP-1 Mechanism for Weight Management
Understanding the science behind Mounjaro vs Wegovy weight loss helps inform your decision. Wegovy's active ingredient, semaglutide, is a GLP-1 receptor agonist that works by mimicking the action of glucagon-like peptide-1, a hormone naturally released by your intestines when you eat. This mechanism reduces appetite by acting on brain appetite centres, promotes feelings of fullness after smaller meals, and may reduce food cravings throughout the day. The once-weekly FlexTouch pen delivers consistent medication levels, supporting sustained appetite control between doses. This targeted approach to weight management makes Wegovy a scientifically-backed option when considering prescription weight loss treatments.
Ordering Process: Simple Access to Prescription Weight Loss
Starting your Mounjaro vs Wegovy weight loss journey through EverydayMeds involves a streamlined three-step process designed for convenience and safety. Our 3-minute online clinical assessment captures essential medical history, current medications, and weight management goals to ensure Wegovy suitability. Following submission, our qualified prescribers review your assessment within 3 working days (or 24 hours with express service), considering contraindications and determining appropriate starting doses. Once approved, your prescription-only medicine ships via next-day delivery in temperature-controlled packaging, maintaining the cold-chain integrity essential for medication effectiveness. This efficient process eliminates lengthy GP appointments whilst ensuring clinical oversight and patient safety throughout your weight loss journey.
Storage and Practical Considerations: Wegovy vs Mounjaro Differences
Practical aspects significantly influence the Mounjaro vs Wegovy weight loss decision, particularly regarding storage requirements. Wegovy demonstrates superior storage flexibility, maintaining stability for up to 6 weeks at room temperature below 30°C once removed from refrigeration, compared to Mounjaro's 21-day room temperature limit. Before first use, store Wegovy between 2-8°C in your refrigerator, away from the freezer compartment. The FlexTouch pen design enables easy self-administration with clear dose windows and automatic needle insertion. Dose escalation follows a mandatory schedule over 16 weeks, reaching the 2.4mg maintenance dose where most patients experience optimal weight loss benefits. This structured approach ensures tolerability whilst maximising therapeutic outcomes.
Prescription Weight Loss: MHRA Licensing and NICE Guidance
The regulatory landscape for Mounjaro vs Wegovy weight loss treatments provides important context for UK patients. Wegovy received MHRA approval for weight management in adults with BMI ≥30, or BMI ≥27 with weight-related comorbidities such as hypertension or type 2 diabetes. NICE Technology Appraisal TA875 specifically recommends Wegovy alongside specialist weight management support, recognising its clinical and cost-effectiveness. The medication carries Black Triangle ▼ status, indicating additional monitoring requirements as part of MHRA's pharmacovigilance programme.
As a prescription-only medicine, Wegovy requires clinical assessment and ongoing prescriber oversight throughout treatment. This regulatory framework ensures patient safety whilst providing access to evidence-based weight loss interventions. EverydayMeds operates under GPhC registration #9012878, guaranteeing genuine medications and adherence to UK pharmaceutical standards when dispensing your weight loss prescription.
Start Your Weight Loss Journey: Wegovy Available Today
Making the Mounjaro vs Wegovy weight loss decision becomes clearer when you have straightforward access to proven treatment options. EverydayMeds stocks comprehensive Wegovy supplies with immediate availability for new patients, eliminating waiting lists common with NHS prescribing. Apply discount codes FIRST40 (new customers) or DOSE25 (returning customers) at checkout to access our competitive pricing structure. Our clinical team supports your journey from initial assessment through maintenance dosing, ensuring optimal outcomes. Both Wegovy and Mounjaro represent advances in prescription weight loss, and our prescribers can help determine which option aligns with your individual circumstances. Visit https://everydaymeds.co.uk/collections/wegovy to begin your 3-minute assessment and take the first step toward meaningful weight management with MHRA-approved medication.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
